02486nas a2200397   4500000000100000000000100001008004100002260001500043653001400058653002900072653002500101653001100126653003500137653002700172653001700199653002300216653002500239653002000264653001500284653003100299653004100330653003300371653001100404653001300415100001400428700001800442700002200460700003200482700001800514700001700532245015100549300001200700490000700712520135500719022001402074       2018                            d  c2018-08-1410aCell Line10aClinical Trials as Topic10aEmbryonic stem cells10aHumans10ainduced pluripotent stem cells10aPluripotent Stem Cells10aPublications10astem cell research10acitation frequencies10aclinical trials10ahESC lines10aHuman Embryonic Stem Cells10ahuman induced pluripotent stem cells10ahuman pluripotent stem cells10aimpact10aResearch1 aAnke Guhr1 aSabine Kobold1 aStefanie Seltmann1 aAndrea E. M. Seiler Wulczyn1 aAndreas Kurtz1 aPeter Löser00aRecent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials  a485-4960 v113 aThe human pluripotent stem cell (hPSC) research landscape is rapidly evolving. To assess possible novel trends in hPSC usage, we analyzed experimental hPSC research published from 2014 to 2016 and compared our data with those of earlier periods. The number of papers describing experimental work involving hPSCs increased further with clear differences in the scientific impact of publications from different countries. Our results confirm the leading position of US-based hPSC research, although to a lesser degree than observed previously. Our data reveal that research into human induced pluripotent stem cells alone surpassed human embryonic stem cell (hESC) research by 2015 and rapidly grew after that. We also report on continuing and even slightly growing research activities in the hESC field as well as on a generally declining rate of the generation of new hESC lines. An increasing portion of new hESC lines represents disease-specific and clinical-grade cell lines. The previously noted usage of only a few early established hESC lines in the vast majority of scientific work is sustained. We also provide a comprehensive overview on clinical trials on the basis of hPSCs. We find that the vast majority of those trials are based on hESC-derived cell products that were generated from an only limited number of relatively old cell lines.  a2213-6711